



Built for the most innovative work in the development and commercialization of CNS therapies

CNS trials have high failure rates and specific challenges—from managing placebo response to effectively harnessing the promise of cell and gene therapies. Count on Precision’s proven expertise to overcome

them. Cross-disciplinary teams ensure that we anticipate roadblocks; industry pioneers help develop novel solutions to complex issues; together we speed your CNS therapies to the patients who need them.

600+
CNS COMMERCIALIZATION
PROJECTS IN THE LAST 4 YEARS

95+
CNS PUBLICATIONS IN
THE LAST 5 YEARS

60
CLINICAL TRIAL
PROJECTS

65+
UNIQUE CNS
CLIENTS

Delivering expertise across 35+ disease states

Neurodegenerative Diseases, Psychiatry, Acute and Chronic Pain

- Alzheimer’s Disease
- Ataxia
- Autism
- Bipolar Depression
- Fragile X Syndrome
- Insomnia
- Major Depressive Disorder
- Migraine
- Multiple Sclerosis
- Muscular Dystrophy
- Neuropathic Pain
- OCD
- Parkinson’s Disease
- PTSD
- Schizophrenia
- Stroke Epilepsy
- Traumatic Brain Injury

Comprehensive and integrated CNS solutions

Accelerating the development of treatments of these complex diseases

We begin with a foundation of precision medicine, applying relevant insights and specialized capabilities to unlock the potential of data—then harnessing it to advance every aspect of drug development and elevate commercial success.



A global footprint and dedicated teams, passionate about bringing life-changing treatments to patients

3000+
EMPLOYEES

30
OF THE TOP 30 BIOPHARMA

210+
NEW DRUG LAUNCHES AND LABEL EXPANSIONS

25+
COUNTRIES WITH ACTIVE TRIALS

7
LABS IN NORTH AMERICA & EUROPE

25+
FORMER MARKET ACCESS DECISION MAKERS

Download your digital copy



Accelerate your CNS therapy
Contact us at info@precisionmedicinegrp.com, or visit our websites to learn how.

© 2022 Precision Medicine Group, LLC. All Rights Reserved.
Rev. 03

